TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03935646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00414440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT02291380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
Study: NCT00002993
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00539786
Drug: Proton pump inhibitor (rabeprazole)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
Study: NCT01692704
Drug: Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
Normalized name: floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications.
Study: NCT04382651
Drug: Standard of Care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study: NCT00004048
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04222725
Drug: TRS01 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed 4 times a day (QID)
Study: NCT04222725
Drug: TRS01 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed QID
Study: NCT04222725
Drug: Placebo eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed QID
Study: NCT01801397
Drug: osteoanabolic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02018250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
Study: NCT02277132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets three times daily orally from randomization until delivery
Study: NCT01910506
Drug: RDEA3170 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03291379
Drug: BTG-002814
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTG-002814 containing 100 mg vandetanib
Study: NCT00607750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eyedrops, BID, 48 weeks
Study: NCT01634347
Drug: Placebo and memory reactivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
Study: NCT01172171
Drug: Melatonin, N-acetyl-5-methoxytryptamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
Study: NCT01172171
Drug: Isotonic saline, Natrium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
Study: NCT00477451
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Alprazolam Placebo
Study: NCT00759473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00581607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day
Study: NCT00581607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01563835
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
Study: NCT00745316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo - 2 capsules bid
Study: NCT01914718
Drug: DA-EPOCH-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
Study: NCT03619785
Drug: Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or IV pain medication as needed.
Study: NCT03322137
Drug: SNA-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegcantratinib ointment
Study: NCT03322137
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment to mimic Pegcantratinib ointment
Study: NCT03429556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
Study: NCT01460836
Drug: Tobramycin solution for inhalation
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01460836
Drug: Aztreonam lysine for inhalation
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04287062
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight and color matched placebo
Study: NCT00501605
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003270
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01855789
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
Study: NCT01855789
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO matching to MTX will be administered orally.
Study: NCT02369510
Drug: Low-dose epinephrine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
Study: NCT02369510
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
Study: NCT02369510
Drug: No epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2ml of preservative-free saline will be added to the standard spinal medications
Study: NCT06209957
Drug: Local corticosteroid injection
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
Study: NCT01418222
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT01418222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT01418222
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous repeating dose
Study: NCT00677144
Drug: XELOX (oxalipaltin+capecitabine)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Study: NCT03103750
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: three 0.5 mcg capsules
Study: NCT03604614
Drug: Without Hyperthermic Intraperitoneal Chemotherapy
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
Study: NCT03461692
Drug: patients under 14 years of age using Reduning injeciton
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
Study: NCT03340805
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride.
Study: NCT01962636
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
Study: NCT01962636
Drug: Mycophenylate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
Study: NCT04056130
Drug: KBL697
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral
Study: NCT00340327
Drug: IMA-638
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02112448
Drug: continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
Study: NCT02112448
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be given every 4 hours for a total of 24 hours.
Study: NCT02112448
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
Study: NCT00210561
Drug: tramadol hydrochloride , acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495077
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 to 60 minutes prior to the start of the infusion~* Tylenol, 600 to 1000mg by mouth or~* Suppository form
Study: NCT02735317
Drug: Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
Study: NCT00534846
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
Study: NCT02752308
Drug: Dilute epinephrine injection
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 1/100000 epinephrine solution along all incision lines
Study: NCT02752308
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
Study: NCT01654575
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 25mg/week for 16 weeks
Study: NCT01654575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a week for 16 weeks
Study: NCT04056130
Drug: KBL697
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral
Study: NCT04056130
Drug: KBL697
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral
Study: NCT04056130
Drug: KBL697
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral
Study: NCT03946306
Drug: 5,25% NaOCl with syringe needle irrigation alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
Study: NCT00683553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV injection of saline
Study: NCT04691856
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study: NCT02114203
Drug: placebo for PDE9i
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose, every 12 hours for 28 days
Study: NCT02114203
Drug: PDE9i
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose, every 12 hours for 28 days
Study: NCT01518699
Drug: Ha44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abametapir Lotion 0.74%
Study: NCT01518699
Drug: Ha44 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ha44 Vehicle Gel without Abametapir
Study: NCT04691856
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study: NCT04291300
Drug: Lutetium-177-PSMA-I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
Study: NCT01225263
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin, 20 mg, twice daily for 6 months
Study: NCT04724486
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage adjustment according to the ovarian response.
Study: NCT03947879
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of L-glutamine twice daily by mouth for 3 months.
Study: NCT04007029
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04762355
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-to-match palovarotene ophthalmic solution vials
Study: NCT01197573
Drug: rTPA Treatment
Normalized name: Sportpac Coldpac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
Study: NCT01009463
Drug: FF/GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
Study: NCT01009463
Drug: GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
Study: NCT02413255
Drug: TAK-020 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-020 placebo-matching oral solution
Study: NCT01742221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous dose
Study: NCT00619541
Drug: Infusional 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
Study: NCT01477632
Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 2 tablets under fasting conditions
Study: NCT01477632
Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 1 tablet under fasting conditions
Study: NCT01469923
Drug: AZD2820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
Study: NCT01469923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
Study: NCT00006669
Drug: EPOCH regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006669
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006669
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01374581
Drug: Quinine + Clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily
Study: NCT02635438
Drug: Unique Pharmaceutical Laboratories, India
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
Study: NCT02635438
Drug: Roxane Laboratories Inc., USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
Study: NCT03074006
Drug: TEW-7197
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg tablets (doses will be determined through dose-escalation part)
Study: NCT00968617
Drug: MK2578
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK2578 1.0 mcg/kg/month
Study: NCT00968617
Drug: MK2578
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK2578 2.0 mcg/kg/month
Study: NCT00968617
Drug: MK2578
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK2578 3.6 mcg/kg/month
Study: NCT01616615
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule / day oral use
Study: NCT01878006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790061
Drug: Traditional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications
Study: NCT01569204
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01569204
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00402350
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Placebo, same number of doses as active comparator in that arm
Study: NCT00402350
Drug: Inhaled Fentanyl 25 mcg
Normalized name: fentanyl Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 1 dose
Study: NCT00402350
Drug: Intravenous Fentanyl 25 mcg
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Fentanyl 25 mcg, single dose
Study: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 2 doses
Study: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 4 doses
Study: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 6 doses
Study: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 12 doses
Study: NCT01842893
Drug: Fentanyl Ethypharm
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
Study: NCT04164212
Drug: Flumist Quadrivalent Nasal Product
Normalized name: FluMist Quadrivalent 2021-2022 Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Study: NCT01011205
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus
Study: NCT02061007
Drug: Optional 18F-FMISO PET scan (18F-fluoromisonidazole)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
Study: NCT00537823
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00537823
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes